CytoDel (United States)
CytoDel utilizes recombinant protein engineering to produce atoxic rBoT derivatives that retain the intraneuronal trafficking properties of native BoT, but which have a controllable safety profile customized to specific indications. CytoDel’s lead program completely inactivates the protease responsible for the toxicity of native (wild type, wt) BoT, enabling the utilization of rBoTs to deliver therapeutic proteins to the cytoplasm of neurons for the treatment of conditions with high unmet
Basic Information
- Category: business
- Website: https://www.cytodel.com/
Documented Facts
- Email: info@cytodel.com (No linked source recorded for this statement.)
Evidence and Sources
- CytoDel (United States) — Official Site (official)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about CytoDel (United States).
- Canonical profile: https://brandsource.ai/brands/cytodel-united-states
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/cytodel-united-states/json-ld
- Citation profile API: https://brandsource.ai/api/brands/cytodel-united-states/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (77/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-21
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
CytoDel utilizes recombinant protein engineering to produce atoxic rBoT derivatives that retain the intraneuronal trafficking properties of native BoT, but which have a controllable safety profile customized to specific indications. CytoDel’s lead program completely inactivates the protease responsible for the toxicity of native (wild type, wt) BoT, enabling the utilization of rBoTs to deliver therapeutic proteins to the cytoplasm of neurons for the treatment of conditions with high unmet
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 structured fact available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.